LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease
Parkinson’s Disease (PD) affects millions of people worldwide with no cure to halt the progress of the disease. Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of PD and, as such, LRRK2 inhibitors are promising therapeutic agents. In the last decade, great progress in the LRRK2...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/11/8/1101 |
| _version_ | 1827685829707825152 |
|---|---|
| author | Dominika Natalia Wojewska Arjan Kortholt |
| author_facet | Dominika Natalia Wojewska Arjan Kortholt |
| author_sort | Dominika Natalia Wojewska |
| collection | DOAJ |
| description | Parkinson’s Disease (PD) affects millions of people worldwide with no cure to halt the progress of the disease. Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of PD and, as such, LRRK2 inhibitors are promising therapeutic agents. In the last decade, great progress in the LRRK2 field has been made. This review provides a comprehensive overview of the current state of the art, presenting recent developments and challenges in developing LRRK2 inhibitors, and discussing extensively the potential targeting strategies from the protein perspective. As currently there are three LRRK2-targeting agents in clinical trials, more developments are predicted in the upcoming years. |
| first_indexed | 2024-03-10T08:59:59Z |
| format | Article |
| id | doaj.art-ff1f45ab1c0b4a2a9a0057f914d1a293 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-10T08:59:59Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-ff1f45ab1c0b4a2a9a0057f914d1a2932023-11-22T06:54:48ZengMDPI AGBiomolecules2218-273X2021-07-01118110110.3390/biom11081101LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s DiseaseDominika Natalia Wojewska0Arjan Kortholt1Faculty of Science and Engineering, University of Groningen, Nijenborg 7, 9747AG Groningen, The NetherlandsFaculty of Science and Engineering, University of Groningen, Nijenborg 7, 9747AG Groningen, The NetherlandsParkinson’s Disease (PD) affects millions of people worldwide with no cure to halt the progress of the disease. Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of PD and, as such, LRRK2 inhibitors are promising therapeutic agents. In the last decade, great progress in the LRRK2 field has been made. This review provides a comprehensive overview of the current state of the art, presenting recent developments and challenges in developing LRRK2 inhibitors, and discussing extensively the potential targeting strategies from the protein perspective. As currently there are three LRRK2-targeting agents in clinical trials, more developments are predicted in the upcoming years.https://www.mdpi.com/2218-273X/11/8/1101kinase inhibitorsneurodegenerative diseasesParkinson’s diseaseprotein–protein interactionssmall GTPasesLRRK2 |
| spellingShingle | Dominika Natalia Wojewska Arjan Kortholt LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease Biomolecules kinase inhibitors neurodegenerative diseases Parkinson’s disease protein–protein interactions small GTPases LRRK2 |
| title | LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease |
| title_full | LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease |
| title_fullStr | LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease |
| title_full_unstemmed | LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease |
| title_short | LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease |
| title_sort | lrrk2 targeting strategies as potential treatment of parkinson s disease |
| topic | kinase inhibitors neurodegenerative diseases Parkinson’s disease protein–protein interactions small GTPases LRRK2 |
| url | https://www.mdpi.com/2218-273X/11/8/1101 |
| work_keys_str_mv | AT dominikanataliawojewska lrrk2targetingstrategiesaspotentialtreatmentofparkinsonsdisease AT arjankortholt lrrk2targetingstrategiesaspotentialtreatmentofparkinsonsdisease |